- Opinion
- [Editor’s View] The key to Xofluza pricing negotiation
- by Nho, Byung Chul Jan 26, 2021 06:00am
- A novel breakthrough influenza treatment Xofluza (baloxavir) by Roche is in a deadlock. Due to COVID-19 pandemic and conditional non-reimbursement status, the flu drug is struggling with the sales dip and marketing. Even before the launch, the drug was expected to easily take over Tamiflu’s market with significantly improved administration
- Company
- Antidiabetic DPP-4 inhibitor breaks record of KRW 600 bn
- by Kim, Jin-Gu Jan 26, 2021 06:00am
- The outpatient prescription volume of antidiabetic dipeptidyl peptidase 4 (DPP-4) inhibitors exceeded over 600 billion won for the first time in the history. The market is steadfastly growing with about 6 percent surge from last year. The experts hint the oral antidiabetic drug market was the key to the growth. The sodium-glucose cotransport
- Policy
- Nexavar's price drops by 30% & Teribone inj ↑31%
- by Kim, Jung-Ju Jan 25, 2021 06:22am
- The price of Bayer Korea's anticancer drug Nexavar 200mg (Sorafenib tosylate) will be reduced by 30% next month. It is a government control. After that, at the end of the year, the benefits that have been given the premium will end and fall further. The price of Dong-A ST's postmenopausal osteoporosis treatment Teribone inj 56.5μg (teriparat
- Company
- KRW 15M incentive to employees assigned to Organon
- by Jan 25, 2021 06:21am
- MSD Korea has promised to pay out an incentive of 15 million won and maintain the employee benefits for those who were notified to be transferred to a new subsidiary, Organon Korea. A pharmaceutical industry source reported today that MSD Korea has signed an agreement with the labor union on Jan. 22 after a long negotiation. First, M
- Company
- Evenity can be prescribed at general hospitals
- by Eo, Yun-Ho Jan 25, 2021 06:21am
- According to related industries, Amgen's bone formation promotion and bone resorption inhibitor Evenity (Romosozumab) has so far been prescribed in Big 5 general hospitals such as SMC, SNUH, Seoul St. hospital, AMC, and Shinchon Severance Hospital, and has passed the drug commitee (DC) of about 30 medical institutions such as Gangnam Severan
- Company
- KanghanLaw scouted Adviser Jaehong Kwon from BMS Korea
- by Eo, Yun-Ho Jan 25, 2021 06:21am
- KanghanLaw hired Jaehong Kwon (60 yrs old), an advisor from BMS, a multinational pharmaceutical company. According to the industry, former chief executive Jaehong Kwon, who retired from Korea BMS in August last year, officially joined KanghanLaw on January 1st. Adviser Kwon is an industry veteran with 34 years of experience who joined J
- Company
- ↑sales of chronic disease drugs & ↓sales of antibiotics
- by Chon, Seung-Hyun Jan 22, 2021 06:28am
- Despite COVID-19 epidemic, the chronic disease treatment market continued to grow. The market for antibiotics and expectorants declined significantly due to the decrease in cold patients due to strengthening hygiene management. According to UBIST, a drug research institute on the 19th, the prescription amount of statin drugs used to treat dys
- Company
- The sales of flu treatment fell 99.6% due to COVID-19
- by Chon, Seung-Hyun Jan 22, 2021 06:26am
- Last year, sales of influenza drugs fell more than 60% from the previous year. The prescription of Tamiflu, the most commonly used, has dropped sharply. In the fourth quarter of last year, the season of full-fledged flu, prescriptions for Tamiflu and generics decreased by more than 99%. As the number of flu patients sharply declined due to reinf
- Company
- Pharmaceutical industry rushes to recruit new GA managers
- by Eo, Yun-Ho Jan 22, 2021 06:26am
- The pharmaceutical industry is hectic seeking for government affairs specialists to recruit. An industry source reported, many of pharmaceutical companies and Korean Research-based Pharmaceutical Industry Association (KRPIA) are in search of new government affairs or market access managers, as their previous members are transitioning to
- Company
- Viatris·Organon's prescription performance declined
- by Kim, Jin-Gu Jan 22, 2021 06:26am
- Sales of major items owned by Viatris and Organon, which were spun off from Pfizer and MSD, are declining in the domestic outpatient prescription market. As of last year, Viatris' outpatient prescriptions fell 4% and Organon's 6% YoY. The decline in prescription results for most major items, such as Viatris' Lipitor·Lyrica and Organon's Sing
